Drug Levels & Therapeutic Monitoring: Timing, Targets, and the Mistakes That Cause Toxicity
Vancomycin has gone AUC/MIC. Phenytoin needs albumin correction. And lithium levels drawn at the wrong time are useless.
NPs in primary care co-manage patients on narrow therapeutic index medications constantly—anticonvulsants, lithium, digoxin, immunosuppressants, and antibiotics. Getting the timing wrong on a drug level makes the result uninterpretable. Getting the target wrong leads to toxicity or treatment failure.
Quick-Reference: Key Drugs
| Drug | Therapeutic Range | When to Draw | Key Pitfall |
|---|---|---|---|
| Vancomycin | AUC/MIC 400–600 (current standard); trough 15–20 is outdated for serious MRSA but still used in some settings | AUC requires 2 levels (1–2 hr post-infusion + trough). For trough-only: draw 30 min before next dose. | AUC/MIC monitoring is now the 2020 ASHP/IDSA guideline standard. Trough-only monitoring overexposes patients to nephrotoxicity. |
| Digoxin | 0.8–2.0 ng/mL (HF benefit at lower range 0.5–0.9) | At least 6 hours post-dose (distribution phase). Ideal: immediately before next dose. | Toxicity risk increases with hypokalemia, hypomagnesemia, hypothyroidism, and renal impairment. Always check K+ and Mg with digoxin levels. |
| Lithium | 0.6–1.2 mEq/L (acute mania: up to 1.5) | 12 hours post-dose (standardized timing is critical) | Dehydration, NSAIDs, ACE inhibitors, and thiazides all increase lithium levels. Toxicity is life-threatening. Monitor renal function and TSH regularly. |
| Phenytoin | 10–20 mcg/mL (total); 1–2 mcg/mL (free) | Trough (before next dose). Steady state in 7–10 days. | Correct for albumin: Adjusted phenytoin = measured level / (0.2 × albumin + 0.1). In hypoalbuminemia, total phenytoin is falsely low but the free (active) level may be therapeutic or toxic. Order free phenytoin in hypoalbuminemic or uremic patients. |
| Valproic acid | 50–100 mcg/mL | Trough. Steady state in 2–4 days. | Monitor LFTs and CBC (hepatotoxicity, thrombocytopenia). Highly protein-bound—free levels needed in hypoalbuminemia. |
| Carbamazepine | 4–12 mcg/mL | Trough. Steady state in 2–4 weeks (auto-induction). | Auto-induces its own metabolism—levels drop after 2–4 weeks even at the same dose. Recheck after auto-induction period. |
| Methotrexate (low-dose) | No routine level monitoring for low-dose (rheumatic/dermatologic use) | N/A for weekly dosing | Monitor CBC, LFTs, creatinine, and albumin. Toxicity manifests as cytopenias, hepatotoxicity, pneumonitis—not as a "high level." Supplement with folic acid 1 mg daily. |
| Tacrolimus | 5–15 ng/mL (varies by organ/time post-transplant) | Trough (12 hours post-dose, immediately before next dose) | Highly variable metabolism. CYP3A4 interactions are extensive (azoles increase levels; carbamazepine, phenytoin decrease). Monitor renal function, glucose, K+, Mg. |
The Universal Rules
- Wait for steady state before checking levels (4–5 half-lives after starting or dose change).
- Timing matters: Trough levels are drawn immediately before the next dose. Drawing at the wrong time makes the result uninterpretable.
- Always check renal function with renally cleared drugs (vancomycin, lithium, digoxin, methotrexate).
- Always check albumin with highly protein-bound drugs (phenytoin, valproic acid).
- Drug interactions: CYP450 inducers (carbamazepine, phenytoin, rifampin) lower levels of co-administered drugs. CYP450 inhibitors (azoles, macrolides, grapefruit) raise them.
Bottom Line
Drug level monitoring is about timing, context, and correction factors. A phenytoin level without albumin correction is meaningless. A lithium level drawn 4 hours post-dose is uninterpretable. A vancomycin trough without considering AUC/MIC is outdated. And for methotrexate, you don't monitor levels—you monitor toxicity through labs. Get the timing right, check the renal function, and always ask "is this level drawn correctly?"
Stay sharp out there.
Comments
Post a Comment